Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Condition:   Arthritis, Rheumatoid Interventions:   Biological: GSK3196165;   Biological: Sarilumab;   Drug: Placebo to GSK3196165/ Sarilumab;   Drug: csDMARDs Sponsors:   GlaxoSmithKline;   Iqvia Pty Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials